{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Patients are considered to have achieved relapse-free survival if they had not experienced either relapse or death (of any cause) at the end of the study.","groups":[{"description":"Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.","id":"OG000","title":"HSC835"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set: The Safety analysis included all enrolled patients who were transplanted with HSC835 (any patient with a date for HSC835 transplant).","reportingStatus":"POSTED","timeFrame":"1 year","title":"Incidence of Relapse-free Survival Within One Year","type":"SECONDARY","unitOfMeasure":"Participants"}